AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

BioLineRx Ltd. Capital/Financing Update 2025

Jul 26, 2025

6692_rns_2025-07-26_ac47592d-f746-4ca7-8172-57f00ddbe162.htm

Capital/Financing Update

Opens in your device viewer

PROSPECTUS SUPPLEMENT false


�� "�	2 380
BIOLINE RX LTD
Corporation no: 513398750	8688
- - -


	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	26/07/2025
	www.isa.gov.il			www.tase.co.il				Reference:	2025-02-055397	Time of broadcast: 21:10 21:10

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000


	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onPROSPECTUS SUPPLEMENT

424B5_July-25_isa.pdf



References of previous documents relating to this matter(the reference does not constitute incorporation by reference):


- - -
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 06/08/2024
Address: HaMa'ayan 2 , Modi'in 7177871 , Israel Tel: 08-6429100 , Fax: 08-6429101
E-mail address: [email protected] Company site: www.biolinerx.com

Previous names of reporting entity:

Name of the Signatory: Serlin Philip Adam Position of Signatory in the reporting corporation: Chief Executive Officer Name of Employer Company:
Address: HaMa'ayan 2 , Modi'in 7177871 Telephone: 08-6429100 Facsimile: 08-6429101 E-mail: [email protected] 1
Israel